ARS Pharmaceuticals (NASDAQ:SPRY) Reaches New 12-Month Low – Time to Sell?

by · The Markets Daily

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report)’s share price reached a new 52-week low on Friday . The stock traded as low as $4.73 and last traded at $4.76, with a volume of 2570805 shares traded. The stock had previously closed at $5.06.

More ARS Pharmaceuticals News

Here are the key news stories impacting ARS Pharmaceuticals this week:

  • Positive Sentiment: Brokerage analysts maintain a consensus rating of “Moderate Buy,” suggesting some Wall Street analysts continue to see potential upside despite the recent weakness. ARS Pharmaceuticals Given Consensus Rating of Moderate Buy
  • Neutral Sentiment: A reported short-interest update showed zero shares sold short both before and after the measurement period, with a zero-day days-to-cover ratio. The figures appear inconsistent or incomplete, so they provide little dependable insight into current trading sentiment.
  • Negative Sentiment: Several investor-rights firms, including Rosen, Bronstein Gewirtz & Grossman, Bragar Eagel & Squire, SBS Law, Faruqi & Faruqi and Kaplan Fox, announced or promoted the pending class action against ARS Pharmaceuticals and certain officers. The case covers investors who purchased SPRY securities from March 9 through June 24, 2026, and alleges violations of federal securities laws. SPRY Investors Have Opportunity to Lead Securities Fraud Lawsuit
  • Negative Sentiment: The allegations reportedly focus on whether ARS and executives—including Chief Commercial Officer Eric Karas—misled investors about the timing of expanded CVS Caremark coverage for neffy, after SPRY shares fell 23.9% in one session. Although the allegations have not been proven, the litigation could create legal costs, prolong uncertainty and weigh on investor confidence. SueWallSt ARS Pharmaceuticals Class Action Reminder

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Cantor Fitzgerald increased their price objective on ARS Pharmaceuticals from $12.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, May 28th. Leerink Partners set a $15.00 target price on ARS Pharmaceuticals in a research report on Tuesday. Wall Street Zen upgraded ARS Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings cut ARS Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, August 17th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $26.40.

Get Our Latest Research Report on ARS Pharmaceuticals

ARS Pharmaceuticals Price Performance

The firm’s 50-day moving average is $6.16 and its 200-day moving average is $7.74. The company has a market capitalization of $473.38 million, a PE ratio of -2.18 and a beta of 1.05. The company has a quick ratio of 3.28, a current ratio of 3.48 and a debt-to-equity ratio of 13.72.

ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.15). ARS Pharmaceuticals had a negative net margin of 184.24% and a negative return on equity of 256.67%. The firm had revenue of $33.66 million for the quarter, compared to analysts’ expectations of $31.32 million. Equities analysts predict that ARS Pharmaceuticals, Inc. will post -1.9 earnings per share for the current fiscal year.

Institutional Trading of ARS Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. BlackRock Inc. bought a new stake in shares of ARS Pharmaceuticals in the 2nd quarter worth approximately $42,544,000. Rubric Capital Management LP grew its holdings in shares of ARS Pharmaceuticals by 247.5% during the 3rd quarter. Rubric Capital Management LP now owns 4,500,000 shares of the company’s stock valued at $45,225,000 after purchasing an additional 3,205,122 shares during the last quarter. Millennium Management LLC purchased a new position in ARS Pharmaceuticals in the 4th quarter worth $36,912,000. Adage Capital Partners GP L.L.C. bought a new stake in ARS Pharmaceuticals in the second quarter worth $30,154,000. Finally, Qube Research & Technologies Ltd bought a new stake in ARS Pharmaceuticals in the third quarter worth $10,400,000. Institutional investors own 68.16% of the company’s stock.

ARS Pharmaceuticals Company Profile

(Get Free Report)

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.

Featured Articles